Sign in

    Omid Farokhzad

    Chief Executive Officer, Chair at Seer Inc
    Board
    Since February 2018
    Age
    55 years
    Education
    Holds an M.A. and M.D. from Boston University and an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management.
    Tenure
    Has been involved with SEER since March 2017 as a board member, co-founded the company, served as Chief Executive Officer since February 2018, became Chair in September 2020, and held the position of President from September 2022 to November 2023.

    Also at Seer Inc

    DH
    David Horn
    President, Chief Financial Officer

    About

    Omid Farokhzad, M.D., has been a transformative force at SEER, having co-founded the company and contributed significantly to its strategic direction since joining as a board member in March 2017.

    During his illustrious career, he has combined his strong academic background with extensive industry experience. He earned an M.A. and M.D. from Boston University and an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management, which laid the foundation for his dual expertise in science and business.

    Before dedicating his primary focus to SEER, he had an accomplished tenure at Harvard Medical School, where he directed the Center for Nanomedicine at Brigham and Women’s Hospital. This period emphasized his commitment to advancing healthcare and biomedical innovation.

    At SEER, his leadership journey is marked by his role as Chief Executive Officer beginning in February 2018, his appointment as Chair in September 2020, and his period as President from September 2022 to November 2023. His visionary and multifaceted approach has driven significant contributions to the company's growth and evolution in the competitive biotechnology landscape.

    $SEER Performance Under Omid Farokhzad

    Past Roles

    OrganizationRoleDate RangeDetails
    SEER, Inc. President September 2022 - November 2023 Former role at SEER
    Dynamics Special Purpose Corp. Executive Chair May 2021 - June 2022 N/A
    Harvard Medical School Professor September 2004 - February 2018 Directed the Center for Nanomedicine at Brigham and Women’s Hospital
    BIND Therapeutics Co-founder N/A Later acquired by Pfizer Inc.
    Selecta Biosciences, Inc. Co-founder / Former Director N/A Clinical-stage biotechnology company
    Tarveda Therapeutics, Inc. Co-founder N/A Clinical-stage biopharmaceutical company

    External Roles

    OrganizationRoleDate Range
    Senti Biosciences Board Member N/A
    Privately-held Companies Board Member N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$600,500AnnualAfter March 2023 merit increase (4.4% increase from $575,484)
    401(k) Plan Matching Contributions$2,500AnnualFixed contribution
    Reimbursement of Commuting Costs$88,532AnnualFixed reimbursement for commuting costs
    Gross-Up Allowance$70,657AnnualFixed gross-up allowance

    Performance Compensation

    Data from  FY 2023

    Annual Cash Incentives

    MetricTarget/ValueAdditional Details
    Target Bonus Percentage85% of base salaryBonus based on corporate objectives: Financial (20%), Commercial (30%), R&D (40%), Organizational (10%)
    Actual Bonus Payout$423,653Represents 83% of the target bonus payout

    Equity Awards

    ComponentUnits/OptionsGrant Date Fair ValuePerformance ThresholdVesting Schedule
    RSUs402,000 units$1,845,180No specific performance condition providedVesting schedule not detailed
    Stock Options650,000 options$2,170,350Must achieve 150% of the grant date price: average price target of $6.89 over 20 trading days 7-year performance period, expiring on 02/15/2030 if conditions are not met